Geron’s royalty deal; Minghui’s new VEGF bispecific data

Plus, news about ADC Ther­a­peu­tics, Celldex and Virac­ta Ther­a­peu­tics:

Geron inks up to $375M roy­al­ty and debt deal: The com­pa­ny now

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.